Brooklyn Health, a neuroscience technology company, secured $6.5 million in seed funding.
The round was led by HealthX, with participation from Metrodora Ventures, Story Ventures, RiverPark Ventures, Laconia Capital, Everywhere Ventures, Hypothesis Studio and Blue Falcon Capital.
WHAT IT DOES
Brooklyn Health measures mental health outcomes in clinical trial participants.
According to Brooklyn Health, central nervous system clinical trials depend heavily on clinical interviews as their primary outcome measure for treatment. The company says the interviews enable the scoring of symptoms via observation and are essential to measure variations in response to treatment.
In a statement, the company said that “clinical interviews are difficult to standardize and scoring is subjective and susceptible to biases,” and could result in undependable outcome measures and is also linked to the placebo response, which may contribute to the high failure rate of CNS clinical trials.
Brooklyn Health said those obstacles might be alleviated with its new electronic clinical outcome assessment platform, Willis.
The Journal of Medical Internet Research (JMIR) describes digital phenotyping as “near real-time data collection from personal digital devices, particularly smartphones, to better quantify the human phenotype.”
According to the company, Willis consists of three parts:
OpenWillis is a shared library of methods in digital phenotyping.
WillisPipeline is intended for organizations collecting behavioral data and can commit computational resources to processing it for clinically meaningful measures.
WillisAPI permits digital health platforms to process the data they collect for measures that can help them better serve their users and customers.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
